Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$3.17M | -$7.86M | -$9.67M | -$8.04M | -$12.5M | -$7.77M |
| Net income | -$3.24M | -$7.90M | -$9.61M | -$7.79M | -$12.3M | -$7.56M |
| EPS (diluted) | — | — | — | -$39.99 | -$80.32 | -$8.16 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.03M | -$5.69M | -$8.83M | -$6.41M | -$11.2M | -$7.76M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $530K | $10.8M | $6.24M | $7.44M | $3.16M | $7.52M |
| Total assets | $605K | $11.6M | $6.94M | $7.98M | $3.53M | $7.86M |
| Total liabilities | $3.78M | $1.52M | $923K | $1.62M | $1.97M | $1.64M |
| Shareholders' equity | -$3.18M | $10.1M | $6.02M | $6.36M | $1.56M | $6.22M |
| Retained earnings | -$28.1M | -$36.0M | -$45.6M | -$53.4M | -$65.7M | -$73.2M |
| Shares (wtd avg diluted) | 1.91M | 4.30M | 770K | 195K | 153K | 926K |
Every figure is extracted from Dermata Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.